Takeda Pharmaceutical has detailed a significant restructuring plan, announcing it will lay off 4,500 workers. The job cuts form a core part of the company’s effort to streamline operations and focus on key therapeutic areas, reflecting ongoing pressures in the global biopharma sector.
Separately, Alumis is discarding a once-highly touted immune drug, marking a setback for the firm. The decision comes after the drug failed to meet expectations, though specific clinical data or trial outcomes were not disclosed in the report.
Hundreds of biotech executives and investors have launched a campaign to push for Rick Pazdur to become the next FDA commissioner. Pazdur, the current director of the FDA’s Oncology Center of Excellence, is widely respected in the industry for his role in oncology drug approvals.
The push for Pazdur’s appointment signals industry desire for continuity and experienced leadership at the FDA. However, the political landscape and competing candidates could influence the final decision, introducing uncertainty around the timeline and outcome.
These developments underscore a dynamic period in biotech, marked by corporate restructuring, clinical pipeline adjustments, and high-stakes regulatory leadership debates.